Evidence map›Paper›PMID 36875086›Full record

ArticleFrontiers in immunology2023

Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study.

Sergio Serrano-Villar, Calvin Cohen, Jason V Baker, Maria João Janeiro, Filipa Aragão, Kathleen Melbourne, Jose Luis Gonzalez, Laura Lara, Connie Kim, Santiago Moreno

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Sergio Serrano-VillarHospital Universitario Ramón y Cajal, Infectious Diseases, Instituto de Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain.
Calvin CohenHIV Medical Affairs, Gilead Sciences Inc., Foster City, CA, United States.
Jason V BakerDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, MN, United States.
Maria João JaneiroMaple Health Group, New York, NY, United States.
Filipa AragãoMaple Health Group, New York, NY, United States.
Kathleen MelbourneHIV Medical Affairs, Gilead Sciences Inc., Foster City, CA, United States.
Jose Luis GonzalezHIV Medical Affairs, Gilead Sciences Inc., Madrid, Spain.
Laura LaraHIV Medical Affairs, Gilead Sciences Inc., Madrid, Spain.
Connie KimHIV Medical Affairs, Gilead Sciences Inc., Foster City, CA, United States.
Santiago MorenoHospital Universitario Ramón y Cajal, Infectious Diseases, Instituto de Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain.
Gilead Sciences (United States) · USGilead Sciences (Spain) · ESHospital Universitario Ramón y Cajal · ESInstituto de Salud Carlos III · ESUniversidade Nova de Lisboa · PTUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.976564.].

Indexed as

antiretroviralHIVinflammationinterleukin-6Markovthree-drug regimentwo-drug regimen

Identifiers

PMID36875086
PMCPMC9978922
OpenAlexW4321086720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.